A Mitochondrial Supplement Improves Function and Mitochondrial Activity in Autism: A double-blind placebo-controlled cross-over trial

Study Design

This two-arm 24-week double-blind, randomized, placebo-controlled, cross-over study with a 1:1 allocation was performed at PCH (Phoenix, AZ) from February 01, 2022 to July 31, 2024.

Randomization

Randomization was performed using the National Cancer Institute Clinical Trial Randomization Tool with a maximally tolerated imbalance of 3. The research pharmacists had exclusive access to the randomization allocation.

Study Procedure

After initial assessments, participants were randomized to active or placebo treatment for 12 weeks. Assessments were repeated at the end of week 12 and then the participants received the opposite treatment that they received in the first 12 weeks. Assessments were again repeated after 12 weeks of treatment. Potential adverse effects (AEs), compliance and concomitant treatments were monitored at every visit and every 1 to 4 weeks. Families were compensated $50 for the screening, baseline, week 12 and week 24 visits.

Intervention

The active treatment was a weight-dosed combination of lemon flavored SpectrumNeeds^® and QNeeds ^®, both produced by NeuroNeeds (Old Lyme, CT; See Table 1), divided equally into two daily doses. SpectrumNeeds^® is a powder with 33 active ingredients that can be mixed into liquid or food. Thirty-one of the 33 supplements do not exceed the Tolerable Upper Intake Level (UL) set by the United States Institute of Medicine. The exceptions are:

1. Niacin is at about the UL. Niacinamide (also known as nicotinamide), the form of niacin in SpectrumNeeds^®, does not cause flushing.

2. Folate exceeds the UL. However, the UL only applied to synthetic folate, also known as folic acid. There is no known UL for non-synthetic folate, which is the type of folate used in SpectrumNeeds^®. Half of the total folate is microbial sourced Quatrefolic™ (6S)-5-Methyltetrahydrofolic acid Glucosamine salt. Half is calcium folinate, which is about one-half the dose recommended for pregnant women with a prior child born with a neural tube defect and one half to one-twenty-fifth the dosing given to children with ASD and suspected cerebral folate deficiency. These dosages are known to be generally well tolerated in ASD children.²⁰

Ubiquinol (reduced form of coenzyme Q10, the principal electron carrier in the respiratory chain) is provided as a QNeeds^® gel capsule. SpectrumNeeds^® could be mixed in any liquid, and the QNeeds^® gel capsule could be opened and the liquid squeezed out into any liquid or food.

Certificate of analysis was provided by an independent analytical service (Eurofins USA, Petaluma CA) with a verification of a potency of at least 99% and undetectable toxins or bacteria contamination.

Placebos had the same look, feel and taste as the active treatments. SpectrumNeeds^® is a silica powder flavored by monk fruit extract, so the inert silica powder with the same favoring was used as a control. Three lemon-flavored placebos were produced for taste testing. Ten staff members, some familiar with SpectrumNeeds^®, were given each placebo paired with the supplement to taste head-to-head. The placebo, which was most indistinguishable, as represented by a 50% choice of the placebo or supplement, was used for the trial. This was also performed by looking at the powder color. In QNeeds^® the ubiquinol is carried by purified water and glycerin colored by caramel liquid, so for the placebo of the same carrier and color was used in the gel capsule without ubiquinol.

Parents were asked about missed doses and returned containers were examined for adherence, which was calculated by the research pharmacy.

Inclusion and Exclusion Criteria

Participants were recruited from the senior author’s ASD clinic at PCH. Inclusion criteria included: (i) a diagnosis of ASD, (ii) age 2 years 6 months to 17 years 3 months years of age; (iii) weight 15 kg to 100 kg; (iv) Childhood Autism Rating Scale, 2^nd Edition (CARS-2) score meeting criteria for ASD; (v) general cognitive ability (GCA) ≥ 30 on the Differential Abilities Scale (DAS); (vi) unchanged complementary, traditional, behavioral and education therapy 8 weeks prior to enrollment; (vii) intention to maintain ongoing therapies constant throughout the trial; and (ix) abnormal mitochondrial activity as assessed by the buccal swab enzymology testing.

Exclusion criteria included: (i) serious behavioral problems (tantrums, aggression, self-injury) for which another treatment is warranted; (ii) significant medical condition that would be incompatible with the treatment; (iii) taking anticonvulsant medication for seizures or active epilepsy; (iv) diagnosis of Mitochondrial Disease; (v) current use of SpectrumNeeds^® or QNeeds^®.

The ASD diagnosis was confirmed using the lifetime version of the Autism Diagnostic Interview-Revised by an independent research reliable rater.

Behavioral and Developmental Outcome Measures

Establishment and Maintenance of Assessment Fidelity

Research staff were trained and certified by a licensed psychologist prior to performing assessments. During the trial a psychologist supervised staff and provided feedback and retraining, if necessary.

Adverse Effect Monitoring

Common medical symptoms were monitored at every visit using the modified Dosage Record Treatment Emergent Symptom (MDOTES) scale, a 34-item form which specifically queries common symptoms of major body systems, activity, sleep, appetite, and general health. At baseline, the severity of any ongoing symptoms was obtained. New symptoms or pre-existing symptoms that significantly worsened were classified as AEs and rated as mild, moderate or severe, and are counted at the highest level of severity. AEs were considered related to the treatment if they started or significantly worsened following the start of the trial. If AEs were persistent or severe, the parents were offered the option of halving the dose or discontinuing the intervention. The dose could only be reduced once and was never increased if reduced.

Suicidality was assessed using the Columbia-Suicide Severity Rating Scale (C-SSRS) and the endorsement of self-injury items on the ABC.

Measures of Mitochondrial Enzymology

We measured the activity of three ETC complexes using a validated buccal swab procedure.³² Buccal cells were collected using four Catch-All Buccal Collection Swabs (Epicentre Biotechnologies, Madison, WI) by firmly pressing against the inner cheek while twirling for 30s. Swabs were clipped, placed in 1.5ml microcentrifuge tubes and transported to the laboratory on dry ice where they are then stored at -80°C.

Buccal extracts were prepared using an ice-cold buffered solution (Buffer A, ABCAM) containing protease inhibitor cocktail and membrane solubilizing non-ionic detergent and cleared of insoluble cellular material by high-speed centrifugation at 4°C. Duplicate aliquots of the protein extract were analyzed for protein concentration using the bicinchoninic acid method (Pierce Biotechnology, Rockford, IL).

Dipstick immunocapture assays measured ETC complex I (C1) activity using 50µg extracted protein.^32–34 Signals were quantified using a Hamamatsu Immunochromato Reader (MS 1000 Dipstick Reader). Raw mABS (milliAbsorbance) results were corrected for protein concentration. ETC complex IV (C4) and citrate synthase (CS) activity were assessed using standard spectrophotometric procedures in 0.5ml reaction volume.

ETC complex II (C2) was measured using extract prepared from 1-2 buccal swabs in ice-cold 300ul STE buffer containing lauryl maltoside and a protease inhibitor cocktail and vortexed for 1min. After centrifugation of the extract at 15,000g for 8min, the supernatant was used. C2 activity was spectrophotometrically determined in succinate-driven reactions by measuring the ubiquinone-initiated oxidation of DCPIP as gauged by the decrease in absorbance at 600nm.³⁵

Specific activities of respiratory complexes were initially expressed as nanomoles per mg protein per minute and normalized to standardized values (z-scores) using the control mean and standard deviation to better represent the deviation of mitochondrial function from normal.

Measures of Mitochondrial Respiration

Statistical Analysis

An intention-to-treat analysis⁴⁴ was performed using PASW Statistics version 28.0.0.0 (IBM SPSS Statistics, Armonk, NY). Graphs were produced using Excel version 14.0 (Microsoft Corp, Redmond, WA). A two-tailed alpha of 5% was used as a cutoff for significance.

Multiple imputation (50) was conducted for missing data since data were lacking at random.^44,45 Sensitivity analysis checked for systematic bias.⁴⁶ Original and processed data were not significantly different (p > 0.05).

Mixed-effects regression models⁴⁷ estimated the effect and effect size of the treatment. The models included the effect of time and a random intercept to account for individual subject mean and variation. The models tested the a priori hypothesis that the change in the outcome measure was different for the active treatment as compared with the placebo treatment by calculating the interaction between treatment and time using a F-test with a p<0.05. For the

Seahorse mitochondrial measurements, the effect of DMNQ was modeled as a polynomial. Additionally, analyses were conducted on the Seahorse data divided into high functioning and low functioning subgroups as defined as above or below the mean VABS Adaptive Behavioral Composite (VABC) score.

A responder analysis was conducted using mixed-model logistic regression. Responders were defined as those that exceeded the minimal clinical important difference (MCID), if it was available. The MCID has been defined for ABC,³ VABS,³ CYBOCS-ASD⁴⁸ and CARS.⁴⁹ For CGI-I and OACIS improvement scales, a rating of ‘much better’ or ‘very much better’ defined response. Age, baseline language and baseline overall development (as indexed by the VABS Adaptive Behavioral Composite Standardized Score) were entered as potential covariates.

The frequency of AEs by severity was evaluated using a Fisher’s exact test.

Participants

Thirty-three participants were screened with 17 failing screenings (Figure 1). Nine participants [Mean (SD) Age 9y 4m (5y 1m); 88% male] were randomized to receive the placebo first (group A) and seven were randomized to receive the treatment first (group B). None of the participants had been diagnosed with genetic disorders, half experienced a neurodevelopmental regression during development, and one had seizures (Supplementary Table 1). Compliance was excellent (>90%) except for the placebo supplement powered (80%). Most participants demonstrated a significant elevation in citrate synthase and a deficit in C1. Characteristics were not significantly different across groups.

Mitochondrial Enzymology

CS was elevated prior to treatment and then significantly decreased toward normal with the supplement treatment in most of the participants (Figure 2A) [F(1,24)=6.49,p<0.05].

• Download figure
• Open in new tab

• Download figure
• Open in new tab

Figure 2. Mitochondrial Function.

The highlighted blue lines represent that average effect for the group Treatment Placebo

Corrected (Figure 2B,C) Complex 1 and 2 activity was not significantly influenced by mitochondrial supplementation. Complex 4 activity corrected for CS [F(1,23.9)=8.28, p<0.01; See Figure 2D] significantly increased with mitochondrial supplementation as compared to placebo.

Mitochondrial Respirometry

The supplement increased the average ALR [treatment x visit: F(1,1515)=3.99,p<0.05, Figure 3A] and prevented ALR from decreasing as physiological stress increased [treatment x visit x DMNQ: F(1,1506)=12.18, p<0.001, Figure 3A], demonstrating improved mitochondrial resilience when the supplement was taken. In comparison, ALR decreased with physiological stress with the placebo treatment.

• Download figure
• Open in new tab

• Download figure
• Open in new tab

Figure 3. Mitochondria Effects

After treatment with the supplement, PLR increased much more as physiological stress was increased [treatment x visit x DMNQ: F(1,1514)=4.41,p<0.05, Figure 3B], suggesting a greater use of PLR to control physiological stress when the supplement was taken, In contrast the opposite effect occurred with the placebo.

Treatment with the supplement significantly increased the average Maximum Respiratory Capacity (MRC) [treatment x visit: F(1,1508)=66.07,p<0.001, Figure 3C], demonstrating that the mitochondrial-targeted supplements improved overall mitochondrial capacity as compared to placebo. MRC did not change with the placebo treatment.

The mitochondrial supplement increased the average Reserve Capacity (RC) [treatment x visit: F(1,1511)=97.61,p<0.001] and change in RC with increasing physiological stress [treatment x visit x DMNQ: F(1,1492)=20.28,p<0.001, Figure 3D], increasing the average RC for low and moderate levels of physiological stress. RC did not change with the placebo treatment.

RC after the treatment dipped below the RC before treatment for high physiological stress levels. This suggests that the mitochondrial-targeted supplements improved mitochondrial resistance to mild and moderate physiological stress but lost this ability at high levels of physiological stress.

We investigated whether the effect of the supplement was dependent on the level of developmental impairment, as defined by the VABC. For all the respiratory parameters except PLR, the effect of the supplement was more pronounced in low functioning group (Figure 4, graphs for the high-functioning subgroup can be found as Supplemental Figure 2).

• Download figure
• Open in new tab

Figure 4. Low VABS ABC Mitochondria Effects

ALR increased independent of physiological stress with the mitochondrial-targeted supplement, but not with placebo, but only for the low-functioning subjects [treatment x visit x VABC (high vs low): ALR F(1,1326)=29.35,p<0.001] (Figure 4A). No effect on ALR was noted in high-functioning subjects (Supplemental Figure 2). Thus, the mitochondrial-targeted supplement improved the ability of the mitochondria to produce ATP for those that were low functioning.

The supplement affected the average MRC and RC [treatment x visit x VABC (high vs low): MRC: F(1,1332)=87.55,p<0.001; RC: F(1,1332)=48.30,p<0.001] and the change in MRC and RC with increasing physiological stress [treatment x visit x DMNQ x VABC (high vs low): MRC: F(1,1323)=13.87, p<0.001; RC: F(1,1323)=20.39, p<0.001] differently for those that were low versus high functioning. Treatment increased the average MRC and RC and allowed the RMC and RC to maintain high respiration as physiological stress increased in low functioning individuals (Figure 4B-C), but not in high functioning individuals (Supplemental Figure 2).

In low functioning individuals, the MRC after treatment was maintained above the MRC before treatment regardless of the level of physiological stress. However, for low functioning individuals, RC after the treatment dipped below the RC before treatment for high physiological stress levels. This suggests that the mitochondrial-targeted supplements improved mitochondrial resistance to mild and moderate physiological stress in low-functioning individuals with ASD.

Behavioral and Cognitive Outcomes

The statistical results of behavioral and cognitive outcomes measures are provided in Table 2.

The VABS VABC, communication, daily living skills and socialization (Figure 5A-D) significantly improved with very-large effect sizes with the supplement as compared to the placebo (Table 2).

• Download figure
• Open in new tab

• Download figure
• Open in new tab

• Download figure
• Open in new tab

Figure 5. Behavior Scales

The highlighted purple lines represent that average effect for the group

The supplement improved ABC social withdrawal, hyperactivity and inappropriate speech (Figure 5E-G) with large effect sizes. Irritability and stereotypy (Supplement Figure 2) and total ABC (Figure 5H) scores improved with the supplement but were not statistically significant. Total ABC, which was borderline significant, had a medium effect size.

The supplement non-significantly reduced caregiver strain (Figure 5I) as compared to the placebo. The supplement did not significantly affect the PRAS-ASD or the SP2 although both improved more with the supplements (Supplementary Figure 4,5).

Two of the OACIS severity scales, anxiety [placebo before: 3.0 (1.6), after 3.4 (1.3), supplement before 3.5 (1.4), after 2.8 (1.5)] and sensory [placebo before: 4.3 (1.4), after 4.8 (1.7), supplement before 4.3 (1.7), after 3.6 (2.0)], improved with the supplement with medium-to-large effect sizes. Neither the CARS (Supplement Figure 6) nor the GCA (Supplement Figure 7) changed with the supplement as compared to placebo. The supplement had little effect on the CYBOS-ASD (Supplement Figure 8).

Responder analysis

More children receiving the supplement had a clinically-significant response on the VABS daily living skills and socialization subscales, ABC social withdrawal and hyperactivity subscales and PRASC verbal communication subscale as compared to the placebo (Table 2). There was no difference in responders for the clinician and psychometrician rated instruments.

Adverse Events

One patient had mild transient constipation, diarrhea, and acid reflux on the mitochondrial supplement. There were no serious adverse events. There were no suicidal attempts or ideations, or significant self-injurious behaviors. The MDOTES found that participants reported decreased appetite significantly more often when taking the supplement. As these were not new events but rather mild worsening of ongoing symptoms, they were not considered AEs (See Supplementary Tables 2,3,4).

Targeted Supplementation Improves Mitochondrial Function

The primary aim of this study was to determine whether the supplement improved mitochondrial function, as measured by buccal cell enzymology and respiration in PBMCs.

Before treatment, CS was markedly elevated, and ETC complex I, II and IV were markedly depressed. After receiving the supplement, CS partially normalized. The elevated CS indicates mitochondrial proliferation which occurs to compensate for poorly functioning mitochondria. Partial normalization of CS indicates that the mitochondrial-targeted supplementation was able to partially restore normal mitochondrial health with 12 weeks of treatment. However, the ETC activity corrected for CS did not change much suggesting that the intrinsic deficits in mitochondrial physiology were not repaired but rather the mitochondria were better able to function with these deficits. Such an effect may have occurred by supporting reactive oxygen species control system and/or supported mitochondrial repair mechanism including fission, fusion and mitophagy to produce more optimal mitochondria. Regardless of the mechanism, these data suggests that mitochondrial function can be partially changed in a short period in children with ASD. Longer treatment may have had a greater effect on normalizing mitochondrial CS and may lead to changes in ETC activity also.

In this study, we found that a mitochondria-targeted supplement increased PBMC respiratory rates, with some respiratory parameters becoming more resilient to physiological stress. For example, as seen in Figure 4, ALR remained steady with increased physiological stress with supplement treatment, while ALR decreased with physiological stress with placebo treatment. With supplement treatment, PLR increased with physiological stress. This most likely indicates the recruitment of proton leak to control physiological stress at the inner mitochondrial membrane. With supplement treatment, MRC and RC remained higher than the baseline MRC and RC throughout the physiological stress challenge with the exception that RC did lose this elevation at high levels of physiological stress. When the participants were separated by developmental ability using the VABC, we found that these observed effects were driven by the lower-functioning individuals with ASD.

ed RC at higher DMNQ levels like we have seen in the past in the subset of LCLs and PBMCs with elevated respiratory rates (e.g., AD-A LCLs).

The MOST was developed to examine the response of the mitochondria to physiological stress.^5,8 This assay allowed the discovery that lymphoblastoid cell lines (LCLs) from a subset of about 33% of children with ASD (called AD-A LCLs), have elevated respiratory rates including double that usual RC.^5,8 Using the MOST we previous found that a consequence of higher respiratory rates, was a greater sensitive to physiological stress. PBMCs derived from a subset of children with ASD and neurodevelopmental regression were also found to have this characteristic.⁷ Interestingly, this same pattern of elevated respiratory rates and greater vulnerability can be induced with prolonged exposure to low levels of oxidative stress in LCLs⁵⁰, and are associated with prenatal exposure to air pollution⁴² or lack of nutritional metal prenatally⁴⁰ in PBMCs from ASD patients.

Targeted Mitochondrial Supplementation Improves Core ASD Symptoms

Several parent-completed outcomes were significant with large effects, including communication, socialization and daily living skills as rated with the VABS, and social withdrawal and hyperactivity as rated with the ABC. All these changes exceeded the MCID, expect communication, indicating that they were both statistically and clinically significant. Although communication did not surpass the MCID, it was found to be rated as improved at a significantly higher rate on the PRASC during the active treatment than during placebo.

Through observation and parental questioning, clinicians judged that the severity of anxiety and sensory issues reduced with the supplement treatment, but they did not note improvements in other areas that were found to be improved on the parent’s rated instruments. It should be appreciated that the clinician only observed the child for a short period of time in an unfamiliar environment, so the changes might not be obvious in this artificial environment. Testing of general cognitive abilities did not improve on the DAS. Such tests require adequate attention and engagement, which may have been subpar.

Comparing to other Treatment Studies

Some of the mainstay treatments for mitochondrial disease are used to treat children with ASD. Two DPBC studies using higher carnitine doses (N=30, 100mg/kg/d,¹⁰ ; N=30, 50mg/k/d⁹) than the current study (10-25mg/kg/d) found improvement in the CARS. Two DBPC studies which added carnitine to risperidone, found improvements in ABC subscales (hyperactivity, social withdrawal, inappropriate speech) similar to the current study.^11,12

An open-label study using 400mg/kg/day of carnitine¹³ and another using 100mg/d of ubiquinol¹⁵ found improvements in verbal communication, similar to the current study, while another study found that improvement in oxidative stress as the results of treating with ubiquinone 30-60mg/d was associated with an improvement in CARS scores.¹⁶

A controlled study which examined a vitamin/mineral supplement similar to the treatment used in this study demonstrated parental-reported improvements in hyperactivity, tantruming and receptive language as well as improvements in ATP, NADH and NADPH blood concentrations.⁵¹

Only one study treated selected individuals with ASD and mitochondrial dysfunction using a method similar to the current study. The treatment contained carnitine, coenzyme Q10 and alpha-lipoic acid.¹⁸ Similar to the current study, improvements occurred in social withdrawal and inappropriate speech subscales of the ABC as well as mitochondrial activity.

The Importance of Treating Mitochondrial Abnormalities in Neurodevelopmental Disorders

Mitochondrial dysfunction is highly prevalent in ASD with estimates ranging from about 30%^5,6 to 80%.⁵² Although this study was limiting to those with abnormal mitochondrial activity, it does not limit the applicability of these findings to a small subset of ASD with mitochondrial dysfunction. Indeed, almost 90% of the ASD population screened for this study. One bias is that participants were managed by a child neurologist well-known in the ASD community for difficult, refractory cases, so the participants would tend to include more lower functioning individuals.

During prenatal neurodevelopment, mitochondria are central for all stages of neurogenesis, regulating neuronal length and complexity, synaptic function and hyperexcitability and have been linked to white matter connectivity.⁵ During postnatal development, the central nervous system heavily relies on multiple mitochondrially-mediated mechanisms, such as synaptic transmission, the glutamate-glutamine cycle and neurotransmitter homeostasis, the glutamate-GABA cycle, neuron-astrocyte shuttling of metabolic substrates like fatty acids and lactate, intercellular mitochondrial trafficking and mitophagy.⁵

Limitations

This study had limitations. First, the small sample size may have limited the sensitivity of the analyses to detect some treatment effects. Second, there was no washout period between the two arms of the study, so carryover effects could have occurred. Third, the single-site design only provides limited generalization of these results. Fourth, although no significant AEs were identified, tolerability data of the mitochondrial-targeted supplement combination would benefit from further study. Fourth, further studies will be needed to determine the optimal dose and treatment period.